Hong Kong: Regulatory Requirements on the Use of Injectable and Infusible Products in Licensed Private Healthcare Facilities

The Department of Health (DH) has updated the regulatory requirements governing the use of injectable and infusible products in licensed Private Healthcare Facilities (PHFs).

Under the updated requirements, all injectable and infusible medical devices used in facilities licensed under the Private Healthcare Facilities Ordinance (Cap. 633) must be listed under the Medical Device Administrative Control System (MDACS) by 1 March 2027.

This requirement includes injectable dermal fillers and mucous membrane fillers, which are specified as medical devices under Clause 2.38(b) of GN-00, Guidance Notes for Definitions and Abbreviations for Medical Device Administrative Control System.

Read the full update here: ORPHF – Update on Regulatory Requirements on the Use of Injectable and Infusible Products in Licensed Private Healthcare Facilities

Purpose of the Update

To introduce updated requirements for injectable and infusible medical devices used in licensed Private Healthcare Facilities in Hong Kong.

The requirement strengthens the role of MDACS listing in the private healthcare sector by requiring affected medical devices used in licensed PHFs to be listed under MDACS by the specified deadline.

Scope of Application

The requirement applies to injectable and infusible medical devices used in Private Healthcare Facilities licensed under the Private Healthcare Facilities Ordinance (Cap. 633).

It is relevant to:

  • Medical device manufacturers
  • Local Responsible Persons (LRPs)
  • Importers and distributors
  • Licensed Private Healthcare Facilities
  • Suppliers of injectable and infusible medical devices

Key Update

MDACS Listing Required by 1 March 2027

All injectable and infusible medical devices used in licensed PHFs must be listed under MDACS by 1 March 2027.

This means affected products supplied or used within licensed PHFs will need to meet the applicable MDACS listing requirements by the deadline.

Injectable Dermal Fillers and Mucous Membrane Fillers

The updated requirement also covers injectable dermal fillers and mucous membrane fillers.

These products are specified as medical devices under Clause 2.38(b) of GN-00: Guidance Notes for Definitions and Abbreviations for Medical Device Administrative Control System.

Manufacturers and suppliers of these products should therefore assess their existing MDACS listing status where the products are intended for use in licensed PHFs.

Practical Implications for Medical Device Companies

The update increases the practical importance of MDACS listing for companies supplying injectable and infusible medical devices to Hong Kong’s private healthcare sector.

Manufacturers and LRPs should review affected product portfolios and determine whether the required MDACS listings are already in place or need to be obtained before the deadline.

Importers and distributors should confirm the listing status of products supplied to licensed PHFs and coordinate with manufacturers and LRPs where listing action is required.

Licensed PHFs should review the injectable and infusible products currently in use or planned for use and ensure that affected devices are listed under MDACS by 1 March 2027.

Key Actions for Companies

Companies should consider:

  • Identifying injectable and infusible medical devices supplied to or used in licensed PHFs.
  • Checking whether affected products are currently listed under MDACS.
  • Identifying products that require MDACS listing before 1 March 2027.
  • Coordinating early with manufacturers, LRPs, distributors, suppliers, and healthcare facilities where regulatory action is required.
  • Reviewing supply planning to reduce the risk of disruption once the requirement takes effect.

References

Read to learn more:

Update on Regulatory Requirements on the Use of Injectable and Infusible Products in Licensed PHFs

GN-00 Guidance Notes for Definitions and Abbreviations for Medical Device Administrative Control System

Implications to Clients

The update expands the practical importance of MDACS listing beyond public-sector healthcare procurement by introducing a specific requirement for injectable and infusible medical devices used in licensed Private Healthcare Facilities.

Manufacturers, LRPs, distributors, and Private Healthcare Facilities should review their product portfolios and ensure that affected devices are listed under MDACS before 1 March 2027.

Early coordination between manufacturers, regulatory representatives, distributors, suppliers, and healthcare facilities is recommended to allow sufficient time for any required listing activities and help minimize potential supply disruptions.

Effective Date

1 March 2027

For Inquiries

For inquiries or support regarding medical device regulatory requirements in Hong Kong, please contact info@nordpacificmed.com.